Technische Universitat Dresden — Sponsor Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

7 Recruiting

5 Completed trials

2 Countries active

21 Unique IMPs

100% Results reported

Phase II

Phase I/II

Phase III: 1 Phase II: 8 Phase I/II: 2 Phase I: 1

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Actinic cheilitis 1 Rectal cancer stage II 1 Myelodysplastic syndrome 1 Diffuse large B-cell lymphoma 1 Colon cancer stage II 1

Top IMPs

VENETOCLAX 3 ATEZOLIZUMAB 1 AUTOLOGOUS PANCREATIC ISLETS 1 GEMTUZUMAB OZOGAMICIN 1 GILTERITINIB 1 IVOSIDENIB 1 MIDOSTAURIN 1 PEMBROLIZUMAB 1 TIRBANIBULIN 1

All trials

12 total

Randomized Evaluation of Treosulfan versus Melphalan conditioning fol-lowed by PTCY in Patients with AML and MDS undergoing allogeneic Trans… Recruiting

2023-507879-21-00 Phase II 1 country
Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation (alloSCT) In Patients with Acute Myeloid Leu… Recruiting

2023-509055-14-00 Phase II 1 country IVOSIDENIB
Sequential Gilteritinib in Combination with Venetoclax and Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mut… Recruiting

2023-507878-41-00 Phase II 1 country GILTERITINIB; VENETOCLAX
Partial or total removal of the pancreas and transplantation of the patient's own islet cells in patients with pancreatic cancer and a high … Recruiting

2023-507773-17-00 Phase II 1 country AUTOLOGOUS PANCREATIC ISLETS
Venetoclax plus azacitidine versus standard intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and NPM1 m… Recruiting

2024-515267-59-00 Phase II 1 country VENETOCLAX
A Phase I trial to establish the safety and maximum tolerated dose of high-affinity autologous BCMA-targeting CAR-T cells in patients with r… Recruiting

2022-502831-20-00 Phase I 1 country
Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia (MOSAIC) Recruiting

2024-514014-13-00 Phase I/II 1 country GEMTUZUMAB OZOGAMICIN; MIDOSTAURIN
A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung (… Ended

2024-515902-15-00 Phase II 1 country ATEZOLIZUMAB
Exploratory study to determine the tolerability and effectiveness of Tirbanibulin in the treatment of Actinic Cheilitis - Cheilitis trial Ended

2022-502807-31-00 Phase II 1 country TIRBANIBULIN
Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax (TUD-RELAX1-070) Ended

2024-514018-12-00 Phase I/II 1 country VENETOCLAX
CIRCULATE Ended

2023-506715-18-00 Phase III 2 countries
MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse Ended

2024-513956-14-00 Phase II 1 country PEMBROLIZUMAB

Showing 1–12 of 12 trials

← All sponsors A–Z